Our Company

We are a biopharmaceutical company on a mission to develop treatments for serious diseases.

We are evaluating activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.

Value-Creating Enablers

Our strategy to deliver impact to patients and create value for stockholders rests on a solid scientific foundation that is enabled by our people and capabilities, external collaborators, and a responsive capital allocation approach.

Startup Spirit, Mature Biotech Expertise

Founded in 2019, Cyclerion is an independent, publicly traded company. We operate with the emboldened spirit, passionate culture, and drive of a startup, while bolstered by the expertise and leadership of a mature biotech. 

Drug-hunting experience

Our board has diverse experience identifying, developing and gaining regulatory approval for novel assets.

We leverage a diverse cross-disciplinary network of external advisors and experts to advance our programs. We do this by:

  1. Engaging leading experts to access additional technologies and expertise to advance our programs
  2. Establishing advisory boards of physicians, patients and payors to provide insights into the unmet medical need and to support the design of clinical trials
  3. Consulting scientific advisory boards made up of veteran drug hunters with broad industry experience and a track record of innovation

We will apply a ‘‘best-owner’’ approach to our compounds whereby we develop and commercialize product candidates independently or through a partner depending on which path we believe will accelerate global patient access to our drugs and offer the greatest risk-adjusted value for our stockholders.

To inquire about partnering with Cyclerion, please reach out to us at partnering@cyclerion.com.

The capital allocation decision making and financial management we use in our business is designed to enable us to continually deploy capital to the most promising opportunities.

Leadership

Regina Graul, PhD

Board of Directors

Errol De Souza, PhD, Chair Regina Graul, PhD Peter Hecht, PhD Michael Higgins Steven Hyman, MD Dina Katabi, PhD 

Contact Us

Cyclerion Therapeutics
245 First Street
Riverview II, 18th Floor
Cambridge, MA 02142

Investor Relations or Media Inquiries: IR@cyclerion.com
Partnering Inquiries: partnering@cyclerion.com

Top